Axsome Therapeutics, Inc. (NASDAQ: AXSM) is frequently evaluated by biotechnology and healthcare investors as a high-potential growth stock centered around its innovative central nervous system (CNS) therapeutic portfolio. Bullish analysts highlight its expanding commercial product lines and late-stage clinical pipeline as strong drivers for future revenue acceleration. However, because clinical-stage and commercial biopharmaceutical equities carry inherent regulatory hurdles, market volatility, and high operational expenses, thorough risk assessment is essential before investing.